Covalon Wins Another $3.5 Million Twelve Month Contract to Supply IV Clear Vascular Access Dressings to
Saudi Arabia
Covalon Technologies Ltd. (the "Company" or "Covalon") (TSXV: COV), an advanced medical technologies company, today announced
that it has won another major contract to supply its IV Clear antimicrobial silicone vascular access dressing to Ministry of Health
facilities in Saudi Arabia at a minimum guaranteed value of $3.5 million over twelve months.
The contract is for a term of one year and delivery of the products under the contract are expected to commence within the next
four months. IV Clear will be used on adults and children to help protect them from infections arising as a result of intravenous
catheters, such as IV catheters, central venous lines, peripherally inserted central catheters, hemodialysis catheters, other
intravascular catheter and percutaneous devices.
“This contract award is massively significant for Covalon in Saudi Arabia and further strengthens Covalon as a major player in
the Middle East,” said Brian Pedlar, Covalon’s Chief Executive Officer. “We fully expect to leverage the minimum commitment of $3.5
million into additional IV Clear revenue in Saudi Arabia. The win validates Covalon’s antimicrobial technology and will help us
secure other contracts in the region and world-wide.”
IV Clear is the only antimicrobial clear silicone vascular access dressing that combines silver and chlorhexidine to provide
broad-spectrum antimicrobial activity for 7 days. The soft silicone adhesive provides greater patient comfort, does not macerate or
damage the skin, and was shown to be up to 10 times less painful upon removal when compared to acrylic adhesives.
In addition to IV Clear, Covalon markets a full line of advanced wound management dressings for both acute and chronic wounds
under its ColActive Plus and CovaWound brands. As well, Covalon is also the only provider of a dual antimicrobial silicone adhesive
surgical dressing called SurgiClear, which is designed to protect surgical incisions by helping to prevent infections and medical
adhesive skin injuries, while providing total incision site visibility to the healthcare provider.
About Covalon
Covalon Technologies Ltd. researches, develops and commercializes new healthcare technologies that help save lives around the
world. Covalon's patented technologies, products and services address the advanced healthcare needs of medical device companies,
healthcare providers and individual consumers. Covalon's technologies are used to prevent, detect and manage medical conditions in
specialty areas such as wound care, tissue repair, infection control, disease management, medical device coatings and
biocompatibility. To learn more about Covalon, visit our website at www.covalon.com
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture
Exchange) accepts responsibility for the adequacy or accuracy of this release.
This news release contains forward-looking statements which reflect the Company's current expectations regarding future
events. The forward-looking statements are often, but not always, identified by the use of words such as "seek", "anticipate",
"plan, "estimate", "expect", "intend" and statements that an event or result "may", "will", "should", "could" or "might" occur or
be achieved and other similar expressions. These forward-looking statements involve risk and uncertainties, including the
difficulty in predicting product approvals, acceptance of and demands for new products, the impact of the products and pricing
strategies of competitors, delays in developing and launching new products, the regulatory environment, fluctuations in operating
results and other risks, any of which could cause results, performance, or achievements to differ materially from the results
discussed or implied in the forward-looking statements. Many risks are inherent in the industry; others are more specific to the
Company. Investors should consult the Company's ongoing quarterly filings for additional information on risks and uncertainties
relating to these forward-looking statements. Investors should not place undue reliance on any forward-looking statements. The
Company assumes no obligation to update or alter any forward-looking statements whether as a result of new information, further
events or otherwise.
Covalon Technologies Ltd.
Brian Pedlar, 905-568-8400 x 233
CEO
bpedlar@covalon.com
Toll free: 1-877-711-6055
Web site:
www.covalon.com
Twitter: @covalon
View source version on businesswire.com: http://www.businesswire.com/news/home/20160809005302/en/